"Sanofi is deeply committed to the field of immunization, and is committed to bringing global innovative products to a broader group of Chinese patients, from prevention to treatment, covering immune inflammation, diabetes, transplantation, prevention and other related fields." said Shi Wang, president of Sanofi Greater China.
During the 6th CIIE, several of its first and only approved innovative products were unveiled. In terms of transplantation, the ROCK2 inhibitor Besudil Mesylate Tablets (Rezurock) made its debut in Asia, used to treat chronic graft versus host disease (cGVHD) patients aged 12 and above who do not respond adequately to glucocorticoids or other systemic therapies.
In addition, its star product in the field of immune inflammation - "Jinbo Baby" Dabitol& Reg; Duprizumab injection has expanded into the respiratory field through the unique mechanism of type 2 inflammation, and the dual indications for chronic obstructive pulmonary disease and asthma have been approved. It has the opportunity to achieve a breakthrough of "zero" progress in biological agents for chronic obstructive pulmonary disease in the past decade.
The first innovative targeted drug in the field of transplantation to fill the treatment gap
Hematopoietic stem cell transplantation is often the main means and hope for achieving disease cure in patients with hematological malignancies such as acute leukemia, lymphoma, multiple myeloma, and non malignant tumors, such as aplastic anemia. However, approximately 30% -70% of patients who receive allogeneic hematopoietic stem cell transplantation will develop chronic graft versus host disease (cGVHD).
CGVHD is one of the main complications after transplantation, which not only leads to fibrosis and inflammation of multiple tissues such as the skin, mouth, eyes, joints, liver, lungs, esophagus, and gastrointestinal tract, but also leads to transplant failure, disease recurrence, and even death in severe cases.
At present, corticosteroids combined with or without CNI are the standard first-line treatment regimen for cGVHD, but the overall efficacy is only 50%. Currently, there are no approved second-line treatment drugs in China.
At the 6th China International Import and Export Fair, Sanofi's first and only approved targeted drug for the treatment of cGVHD, bezuracil mesylate tablets (REZUROCK), made a significant debut in Asia. At the same time, the first report on the development and planning of hematopoietic stem cell transplantation in China was released, helping to accelerate the development of China's hematopoietic stem cell transplantation industry.
It is reported that REZUROCK is the first and only targeted drug approved in China for the treatment of chronic graft-versus-host disease (cGVHD) in patients aged 12 and above who do not respond adequately to glucocorticoids or other systemic therapies.
Clinical research data shows that the overall response rate (ORR), 6-month failure free survival rate (FFS), and 2-year overall survival rate of bezudil mesylate tablets (REZUROCK) can reach 75%, 75%, and 89%, respectively. REZUROCK can significantly reduce hormone dosage, even discontinue hormone use, and significantly improve pulmonary cGVHD symptoms.
REZUROCK was first approved for sale in the United States in July 2021 and officially approved by the National Drug Administration (NMPA) of China on August 1 of this year.
At the site of the 6th International Expo, Sanofi reached an agreement with BK PHARMA-CEUTICALS and Yehui Pharmaceutical to withdraw Sanofi's exclusive right to develop and commercialize bezudil mesylate tablets in Chinese Mainland. Sanofi's perfect commercialization team, with years of experience in transplantation, will make bezudil mesylate tablets quickly benefit more patients with cGVHD.
Executive Deputy Director of the National Center for Clinical Medical Research on Hematological Diseases, Chairman of the Hematology Branch of the Chinese Medical Association, Professor Wu Depei, Director of the Hematology Department of the First Affiliated Hospital of Suzhou University, pointed out that "the indications for the second-line treatment of cGVHD with bezuracil mesylate tablets (REZUROCK) have been approved, filling the gap in this treatment field. Chinese hematologists look forward to the prompt launch of REZUROCK tablets, providing new treatment opportunities for Chinese cGVHD patients
Changing the treatment pattern, becoming the first "dual talent" in the field of chronic respiratory diseases to enter the Bo market
As a beneficiary of the "spillover effect" of Weibo, Sanofi once again brings its star product Dabitol& Reg; On the basis of covering the five major indications in the field of dermatology, we will focus on the huge unmet demand in the field of chronic respiratory diseases in China, showcase cutting-edge clinical achievements in the field of chronic obstructive pulmonary disease and new indications for type 2 asthma, and continue to accelerate the introduction of globally leading innovative products and solutions to China.
It is reported that there has been no breakthrough in biological therapy in the field of chronic obstructive pulmonary disease for over a decade.
Professor Zheng Jinping from the First Affiliated Hospital of Guangzhou Medical University and Guangzhou Institute of Respiratory Health introduced that a recent evaluation of dabitol& Reg; The efficacy and safety of darbitol in adult chronic obstructive pulmonary disease in phase 3 clinical study BOREAS results showed that; Reg; On the basis of triple inhalation (ICS+LABA+LAMA) or double bronchiectasis (LABA+LAMA) treatment, the incidence of moderate to severe acute exacerbation can be further significantly reduced by 30%, improving lung function, quality of life, and respiratory symptoms. Dabitol& Reg; At present, it is the first and only biological agent that can achieve this benefit in COPD, achieving a breakthrough of "zero" in innovative biological therapy for COPD in the past decade.
In terms of asthma, there are 45.7 million patients over the age of 20 in China, with 55% -70% of asthma patients in a state of poor control. About 90% of asthma with poorly controlled medium to high dose ICS treatment plans is driven by type 2 inflammation.
Dabitol& Reg; After expanding the indications for asthma, it can suppress the level of type 2 inflammation in asthma, significantly reduce the acute attack rate, quickly and persistently improve lung function and asthma control, and provide targeted "etiological" treatment options for patients with poorly controlled asthma.
Shen Huahao, Director of the Institute of Respiratory Diseases at Zhejiang University, stated: We need to continue to promote the precise and standardized diagnosis and treatment of chronic airway inflammatory diseases, strengthen medical quality management, and help patients with chronic airway inflammatory diseases achieve higher treatment goals. The CIIE is a stage of innovation, and the application of biological agents will be a new milestone. We look forward to seeing new targeted biological agents bring benefits to more patients with chronic airway inflammatory diseases
China is one of Sanofi's most important strategic markets. China's increasingly open market environment and continuously optimized policies have provided us with solid confidence in continuing to deepen our efforts in the Chinese market, "said Shi Wang.